Brokerages expect Recro Pharma Inc (NASDAQ:REPH) to report ($0.67) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Recro Pharma’s earnings, with estimates ranging from ($0.91) to ($0.51). Recro Pharma reported earnings per share of ($0.48) during the same quarter last year, which would suggest a negative year over year growth rate of 39.6%. The firm is scheduled to announce its next earnings report on Thursday, November 8th.
According to Zacks, analysts expect that Recro Pharma will report full year earnings of ($2.46) per share for the current year, with EPS estimates ranging from ($2.70) to ($2.33). For the next year, analysts expect that the firm will post earnings of ($2.48) per share, with EPS estimates ranging from ($4.21) to ($0.10). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Recro Pharma.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($1.34) by $0.72. Recro Pharma had a negative net margin of 75.19% and a negative return on equity of 144.84%. The firm had revenue of $21.74 million for the quarter, compared to analyst estimates of $16.81 million.
Several equities analysts have recently commented on REPH shares. ValuEngine upgraded shares of Recro Pharma from a “sell” rating to a “hold” rating in a report on Thursday, June 28th. Roth Capital set a $9.00 price objective on shares of Recro Pharma and gave the stock a “buy” rating in a report on Saturday, May 26th. Zacks Investment Research upgraded shares of Recro Pharma from a “sell” rating to a “hold” rating in a report on Thursday, May 31st. Oppenheimer set a $18.00 price objective on shares of Recro Pharma and gave the stock a “buy” rating in a report on Wednesday, August 8th. Finally, Janney Montgomery Scott decreased their price objective on shares of Recro Pharma from $21.00 to $11.00 and set a “fair value” rating on the stock in a report on Thursday, May 24th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $12.63.
Several hedge funds have recently modified their holdings of the company. Jump Trading LLC purchased a new stake in Recro Pharma during the 1st quarter worth approximately $124,000. Citadel Advisors LLC purchased a new stake in Recro Pharma during the 1st quarter worth approximately $126,000. Cubist Systematic Strategies LLC purchased a new stake in Recro Pharma during the 1st quarter worth approximately $139,000. Oppenheimer & Co. Inc. purchased a new stake in Recro Pharma during the 2nd quarter worth approximately $154,000. Finally, Monarch Partners Asset Management LLC purchased a new stake in Recro Pharma during the 2nd quarter worth approximately $178,000. Hedge funds and other institutional investors own 55.86% of the company’s stock.
Shares of REPH stock opened at $8.50 on Friday. The company has a current ratio of 1.59, a quick ratio of 1.42 and a debt-to-equity ratio of 2.22. Recro Pharma has a one year low of $4.78 and a one year high of $13.05. The company has a market capitalization of $160.57 million, a PE ratio of -4.27 and a beta of -0.81.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Recommended Story: Price to Earnings Ratio (PE), For Valuing Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.